Suggested remit: To appraise the clinical and cost effectiveness of tucatinib with trastuzumab and capecitabine within its marketing authorisation for treating HER2-positive unresectable or metastatic advanced breast cancer after 2 or more anti-HER2 therapies.
Status In progress
Process STA 2018
ID number 3828

Project Team

Project lead Michelle Adhemar

Email enquiries


Key events during the development of the guidance:

Date Update
09 November 2020 - 07 December 2020 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
05 August 2020 In progress. DHSC referral received

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance